
MD, Dr.
Lâm Quốc Trung
Deputy Head of the Department of Cancer Chemotherapy
In my medical career journey, I always hold the belief: "Treat with intelligence, care with heart". For me, cancer patients need not only a treatment regimen but also a solid spiritual support. I continuously update modern medical advances to provide the best living opportunity for patients. However, above all is empathy and dedicated companionship, because the ultimate goal is not only to extend lifespan but also quality of life and to light hope for each life.
- Sáng thứ năm
Write your review
Patient rating
No review
2019: Specialist doctor level II in Oncology, University of Medicine and Pharmacy at Ho Chi Minh City
2012: Specialist doctor level I in Oncology, University of Medicine and Pharmacy at Ho Chi Minh City
2001: General practitioner, Training and Development Center for Medical Officers, Ho Chi Minh City.
Teaching experience
- 2024 - 2025: Visiting lecturer in Hematology at University of Medicine and Pharmacy at Ho Chi Minh City
Clinical experience
- 2021 - present: Deputy Head of Chemotherapy Department, University Medical Center Ho Chi Minh City.
- 2014 - 2020: Attending physician at Chemotherapy Department, University Medical Center Ho Chi Minh City.
- 2008 - 2013: Deputy Head of Oncology Department, Thong Nhat Hospital.
- 2007 - 2010: Worked at Oncology Division, Thong Nhat Hospital.
- 2001 - 2006: Attending physician, Internal Medicine Department, Thong Nhat Hospital.
- Member of the executive board of the Ho Chi Minh City Cancer Society and the Ho Chi Minh City Gastrointestinal Surgery Association.
- Vice President of the Ho Chi Minh City Cancer Immunotherapy Society.
- 2025 Bone Marrow Infiltration with Anemia and Thrombocytopenia, Rare Initial Symptoms of Breast Cancer
- 2025 Psychosocial Support Needs and Associated Factors among Cancer Patients: A Hospital-Based, Single-Center Cross-Sectional Study in Vietnam
- 2025 Preoperative chemotherapy with a modified docetaxel, cisplatin and S-1 regimen, followed by gastrectomy and lymphadenectomy for gastric cancer with bulky lymph nodes
- 2020 Assessing the Treatment Outcomes of EOX Regimen in Inoperable Advanced or Metastatic Gastric Cancer Patients
- 2020 Comparison of Post-Progression Survival in Advanced EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with First-Line Osimertinib versus Standard EGFR-TKIs
